Profile data is unavailable for this security.
About the company
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-89.30m
- Incorporated2010
- Employees93.00
- LocationCalithera Biosciences Inc343 Oyster Point Blvd # 200SOUTH SAN FRANCISCO 94080-1913United StatesUSA
- Phone+1 (650) 870-1000
- Fax+1 (302) 655-5049
- Websitehttp://www.calithera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exicure Inc | 16.78m | -21.96m | 203.24m | 48.00 | -- | 2.77 | -- | 12.11 | -0.267 | -0.267 | 0.1976 | 0.8418 | 0.1814 | -- | 516.40 | 578,724.10 | -23.73 | -- | -26.75 | -- | -- | -- | -130.87 | -- | -- | -- | 0.1835 | -- | 998.31 | -- | -17.36 | -- | -- | -- |
| Abeona Therapeutics Inc | 7.00m | -84.84m | 208.88m | 88.00 | -- | 1.56 | -- | 29.84 | -1.04 | -1.04 | 0.0838 | 1.36 | 0.0463 | -- | 2.00 | 79,545.45 | -56.16 | -29.61 | -69.78 | -32.36 | -- | -- | -1,211.96 | -3,412.06 | -- | -33.94 | 0.015 | -- | -100.00 | -- | -34.61 | -- | -- | -- |
| Idera Pharmaceuticals Inc | 0.00 | -87.24m | 209.74m | 36.00 | -- | -- | -- | -- | -2.80 | -2.80 | 0.00 | -0.921 | 0.00 | -- | -- | 0.00 | -152.30 | -60.33 | -187.44 | -70.81 | -- | -- | -- | -1,383.99 | -- | -328.74 | -- | -- | 118.73 | 81.76 | -41.21 | -- | -60.14 | -- |
| Sesen Bio Inc | 11.24m | -41.09m | 213.41m | 25.00 | -- | -- | -- | 18.99 | -0.3841 | -0.3841 | 0.10 | -0.1339 | 0.0984 | -- | -- | 449,440.00 | -35.85 | -48.95 | -39.06 | -52.68 | -- | -- | -364.37 | -642.70 | -- | -- | -- | -- | -- | -- | -219.06 | -- | -0.1464 | -- |
| OptiNose Inc | 43.85m | -100.92m | 214.05m | 102.00 | -- | 7.73 | -- | 4.88 | -2.20 | -2.20 | 0.9522 | 0.5315 | 0.2654 | 1.07 | 3.08 | 429,911.80 | -61.09 | -- | -78.51 | -- | 83.23 | -- | -230.14 | -- | 3.76 | -7.99 | 0.7914 | -- | 390.18 | -- | -3.18 | -- | -- | -- |
| Calithera Biosciences Inc | 0.00 | -89.30m | 218.73m | 93.00 | -- | 1.78 | -- | -- | -1.39 | -1.39 | 0.00 | 1.74 | 0.00 | -- | -- | 0.00 | -60.74 | -40.33 | -69.84 | -45.98 | -- | -- | -- | -503.98 | -- | -- | 0.00 | -- | -100.00 | -- | -64.49 | -- | -58.31 | -- |
| Evolus Inc | 55.41m | -66.83m | 223.42m | 125.00 | -- | 6.37 | -- | 4.03 | -2.02 | -2.02 | 1.68 | 1.04 | 0.2781 | 1.97 | 5.96 | 235,787.20 | -33.54 | -- | -37.15 | -- | 73.55 | -- | -120.60 | -- | 10.03 | -7.48 | 0.7912 | -- | -- | -- | -92.11 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -26.78m | 223.68m | 8.00 | -- | 1.08 | -- | -- | -7.34 | -7.34 | 0.00 | 18.50 | 0.00 | -- | -- | 0.00 | -25.68 | -51.50 | -26.38 | -57.38 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | 27.68 | -- | -20.69 | -- |
| Eton Pharmaceuticals Inc | 417.00k | -22.98m | 223.98m | 5.00 | -- | 139.87 | -- | 537.11 | -1.18 | -1.18 | 0.0214 | 0.0661 | 0.0335 | -- | -- | 24,529.41 | -184.56 | -- | -223.36 | -- | -6.71 | -- | -5,510.55 | -- | 2.51 | -35.36 | 0.8347 | -- | -- | -- | 50.79 | -- | -- | -- |
| Axcella Health Inc | 0.00 | -57.10m | 224.87m | 66.00 | -- | 2.50 | -- | -- | -2.14 | -2.14 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -49.75 | -- | -53.11 | -- | -- | -- | -- | -- | -- | -23.06 | 0.2206 | -- | -- | -- | -63.11 | -- | -- | -- |
| Tyme Technologies Inc | 0.00 | -28.36m | 226.50m | 18.00 | -- | 15.62 | -- | -- | -0.2333 | -0.2333 | 0.00 | 0.1114 | 0.00 | -- | -- | 0.00 | -142.92 | -- | -192.92 | -- | -- | -- | -- | -- | -- | -13.18 | 0.0119 | -- | -- | -- | 33.30 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -59.59m | 228.74m | 28.00 | -- | 1.86 | -- | -- | -2.22 | -2.22 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -47.54 | -- | -50.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -138.21 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -21.05m | 228.76m | 7.00 | -- | 0.9477 | -- | -- | -22.51 | -22.51 | 0.00 | 16.87 | 0.00 | -- | -- | 0.00 | -20.26 | -64.74 | -21.05 | -70.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.84 | -- | -- | -- |
| ADMA Biologics Inc | 40.30m | -66.90m | 229.75m | 313.00 | -- | 3.05 | -- | 5.70 | -0.8653 | -0.8653 | 0.5248 | 0.7965 | 0.2459 | 0.9792 | 5.90 | 128,756.40 | -40.82 | -60.76 | -45.18 | -70.31 | -33.67 | -39.80 | -166.01 | -224.62 | 4.24 | -4.98 | 0.5762 | -- | 72.79 | 37.76 | 26.56 | -- | 10.41 | -- |
| Evofem Biosciences Inc | 278.00k | -114.43m | 230.02m | 53.00 | -- | 5.72 | -- | 827.42 | -1.93 | -1.93 | 0.0047 | 0.4947 | 0.0037 | -- | 0.2843 | 5,245.28 | -151.24 | -239.25 | -323.65 | -402.08 | 21.94 | -- | -41,161.15 | -- | 1.51 | -2.46 | 0.5444 | -- | -- | -- | 36.37 | -- | 55.43 | -- |
| Neubase Therapeutics Inc | 0.00 | -17.38m | 233.63m | 3.00 | -- | 7.46 | -- | -- | -0.9026 | -0.9026 | 0.00 | 1.35 | 0.00 | -- | -- | -- | -74.01 | -87.20 | -84.14 | -100.52 | -- | -- | -- | -- | -- | -63.09 | 0.0044 | -- | -- | -- | 33.47 | -- | 31.12 | -- |
Data as of Jan 22 2021. Currency figures normalised to Calithera Biosciences Inc's reporting currency: US Dollar USD
58.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| PRIMECAP Management Co.as of 30 Sep 2020 | 10.06m | 14.26% |
| Federated Global Investment Management Corp.as of 30 Sep 2020 | 7.45m | 10.56% |
| BVF Partners LPas of 30 Sep 2020 | 4.59m | 6.50% |
| BlackRock Fund Advisorsas of 30 Sep 2020 | 4.30m | 6.10% |
| Point72 Asset Management LPas of 30 Sep 2020 | 3.73m | 5.28% |
| The Vanguard Group, Inc.as of 30 Sep 2020 | 3.37m | 4.77% |
| Great Point Partners LLCas of 30 Sep 2020 | 2.92m | 4.14% |
| Wellington Management Co. LLPas of 30 Sep 2020 | 2.11m | 3.00% |
| Dimensional Fund Advisors LPas of 30 Sep 2020 | 1.49m | 2.11% |
| SSgA Funds Management, Inc.as of 30 Sep 2020 | 1.29m | 1.83% |
More ▼
Data from 30 Sep 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
